Continued investment in advanced data analytics technology accelerates AI accessibility and adoption across the global commercial life sciences industrySAN FRANCISCO, Oct. 27, 2021 (GLOBE NEWSWIRE)
Published: Dec 18, 2020 By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk.
Share:
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) Aktana, the pioneer in AI-driven intelligent engagement for the life sciences industry, announced major milestones of 2020, including key executive hires, expanded customer partnerships, and the launch of its next-generation
Contextual Intelligence Engine. Aktana s growth reflects increasing demand for AI capabilities to enable more effective multichannel customer engagement in life sciences, as evidenced by their nearly 300 deployments across more than 20 therapeutic areas. The company is well-positioned for continued growth within the AI in Life Sciences industry, which is expected to be valued at $4.8 billion by the year 2025, according to a report by Mordor Intelligence.